Hepatitis C and steatosis

Clinics in Liver Disease

Volumn 8, Issue 4, 2004, Pages 881-892

  Dev, Anouk ^a   Patel, Keyur ^a   McHutchison, John G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTIINFECTIVE AGENT; ANTIOXIDANT; ANTIVIRUS AGENT; COLLAGEN TYPE 1; FATTY ACID; HOST FACTOR 1; INSULIN; INSULIN SENSITIZING AGENT; LEPTIN; LOW DENSITY LIPOPROTEIN; PEGINTERFERON; PIOGLITAZONE; REACTIVE OXYGEN METABOLITE; RETINOID X RECEPTOR; RIBAVIRIN; ROSIGLITAZONE; SCLEROPROTEIN; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR; VERY LOW DENSITY LIPOPROTEIN; VIRUS PROTEIN;

ADIPOSE TISSUE; ALCOHOL CONSUMPTION; BODY MASS; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE COURSE; DISEASE EXACERBATION; DOWN REGULATION; EVALUATION; EXERCISE; GENE MUTATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; LIPID STORAGE; LIPOGENESIS; LIPOLYSIS; LIVER BIOPSY; LIVER CELL; LIVER CELL CARCINOMA; LIVER FIBROSIS; MITOCHONDRIAL TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; RISK FACTOR; SEX DIFFERENCE; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VIRUS LOAD; WEIGHT REDUCTION;

ANTIVIRAL AGENTS; DISEASE PROGRESSION; FATTY LIVER; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; RISK FACTORS;

EID: 4744361139     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2004.06.007     Document Type: Review

References (52)

1. Z.D. Goodman, and K.G. Ishak Histopathology of hepatitis C virus infection Semin Liver Dis 15 1 1995 70 81
2. L. Rubbia-Brandt, R. Quadri, K. Abid, E. Giostra, P.J. Male, and G. Mentha Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3 J Hepatol 33 1 2000 106 115
3. D. Kumar, G.C. Farrell, C. Fung, and J. George Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response Hepatology 36 5 2002 1266 1272
4. A.J. Czaja, H.A. Carpenter, P.J. Santrach, and S.B. Moore Host- and disease-specific factors affecting steatosis in chronic hepatitis C J Hepatol 29 2 1998 198 206
5. L.E. Adinolfi, R. Utili, A. Andreana, M.F. Tripodi, M. Marracino, and M. Gambardella Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C Dig Dis Sci 46 8 2001 1677 1683
6. T. Poynard, V. Ratziu, J. McHutchison, M. Manns, Z. Goodman, and S. Zeuzem Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C Hepatology 38 1 2003 75 85
7. H.M. Patton, K. Patel, C. Behling, D. Bylund, L. Blatt, and M. Vallee The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients J Hepatol 40 2004 484 490
8. J.M. Hui, A. Sud, G.C. Farrell, P. Bandara, K. Byth, and J.G. Kench Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression Gastroenterology 125 6 2003 1695 1704
9. K. Ohata, K. Hamasaki, K. Toriyama, K. Matsumoto, A. Saeki, and K. Yanagi Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection Cancer 97 12 2003 3036 3043
10. A.J. Sanyal American Gastroenterological Association AGA technical review on nonalcoholic fatty liver disease Gastroenterology 123 5 2002 1705 1725
11. M.A. Gerber, K. Krawczynski, M.J. Alter, R.E. Sampliner, and H.S. Margolis Histopathology of community acquired chronic hepatitis C. The Sentinel Counties Chronic Non-A, Non-B Hepatitis Study Team Mod Pathol 5 5 1992 483 486
12. N. Bach, S.N. Thung, and F. Schaffner The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis Hepatology 15 4 1992 572 577
13. A.J. Sanyal, M.J. Contos, R.K. Sterling, V.A. Luketic, M.L. Shiffman, and R.T. Stravitz Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome Am J Gastroenterol 98 9 2003 2064 2071
14. A.J. Czaja, and H.A. Carpenter Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis Gastroenterology 105 6 1993 1824 1832
15. G. Barba, F. Harper, T. Harada, M. Kohara, S. Goulinet, and Y. Matsuura Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets Proc Natl Acad Sci USA 94 4 1997 1200 1205
16. K. Moriya, H. Yotsuyanagi, Y. Shintani, H. Fujie, K. Ishibashi, and Y. Matsuura Hepatitis C virus core protein induces hepatic steatosis in transgenic mice J Gen Virol 78 Pt 7 1997 1527 1531
17. R.G. Hope, and J. McLauchlan Sequence motifs required for lipid droplet association and protein stability are unique to the hepatitis C virus core protein Gen Virol J 81 Pt 8 2000 1913 1925
18. S.T. Shi, S.J. Polyak, H. Tu, D.R. Taylor, D.R. Gretch, and M.M. Lai Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins Virology 292 2 2002 198 210
19. G. Perlemuter, A. Sabile, P. Letteron, G. Vona, A. Topilco, and Y. Chretien Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis FASEB J 16 2 2002 185 194
20. V. Agnello, G. Abel, M. Elfahal, G.B. Knight, and Q.X. Zhang Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor Proc Natl Acad Sci USA 96 22 1999 12766 12771
21. F. Negro Hepatitis C virus and liver steatosis: is it the virus? Yes it is, but not always Hepatology 36 5 2002 1050 1052
22. M. Okuda, K. Li, M.R. Beard, L.A. Showalter, F. Scholle, and S.M. Lemon Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein Gastroenterology 122 2 2002 366 375
23. L.E. Adinolfi, M. Gambardella, A. Andreana, M.F. Tripodi, R. Utili, and G. Ruggiero Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity Hepatology 33 6 2001 1358 1364
24. W. Aldhahi, and O. Hamdy Adipokines, inflammation, and the endothelium in diabetes Curr Diab Rep 3 4 2003 293 298
25. S.H. Mehta, F.L. Brancati, M.S. Sulkowski, S.A. Strathdee, M. Szklo, and D.L. Thomas Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States Ann Intern Med 133 8 2000 592 599
26. B.C. Martin, J.H. Warram, A.S. Krolewski, R.N. Bergman, J.S. Soeldner, and CR. Kahn Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study Lancet 340 8825 1992 925 929
27. B.B. Kahn, and J.S. Flier Obesity and insulin resistance J Clin Invest 106 4 2000 473 481
28. J.P. Ong, Z.M. Younossi, C. Speer, A. Olano, T. Gramlich, and N. Boparai Chronic hepatitis C and superimposed nonalcoholic fatty liver disease Liver 21 4 2001 266 271
29. A. Monto, J. Alonzo, J.J. Watson, C. Grunfeld, and T.L. Wright Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol Hepatology 36 3 2002 729 736
30. L.M. Kaplan Leptin, obesity, and liver disease Gastroenterology 115 4 1998 997 1001
31. S. Chitturi, G. Farrell, L. Frost, A. Kriketos, R. Lin, and C. Fung Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology 36 2 2002 403 409
32. J. Crespo, M. Rivero, E. Fabrega, A. Cayon, J.A. Amado, and M.T. Garcia-Unzeta Plasma leptin and TNF-alpha levels in chronic hepatitis C patients and their relationship to hepatic fibrosis Dig Dis Sci 47 7 2002 1604 1610
33. A.I. Su, J.P. Pezacki, L. Wodicka, A.D. Brideau, L. Supekova, and R. Thimme Genomic analysis of the host response to hepatitis C virus infection Proc Natl Acad Sci USA 99 24 2002 15669 15674
34. M.R. Teli, O.F. James, A.D. Burt, M.K. Bennett, and CP. Day The natural history of nonalcoholic fatty liver: a follow-up study Hepatology 22 6 1995 1714 1719
35. J. Westin, H. Nordlinder, M. Lagging, G. Norkrans, and R. Wejstal Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients Hepatol J 37 6 2002 837 842
36. L.F. Hourigan, G.A. Macdonald, D. Purdie, V.H. Whitehall, C. Shorthouse, and A. Clouston Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis Hepatology 29 4 1999 1215 1219
37. L. Castera, C. Hezode, F. Roudot-Thoraval, A. Bastie, E.S. Zafrani, and J.M. Pawlotsky Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies Gut 52 2 2003 288 292
38. I.J. Hickman, E.E. Powell, J.B. Prins, A.D. Clouston, S. Ash, and D.M. Purdie In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy J Hepatol 39 6 2003 1042 1048
39. L. Rubbia-Brandt, P. Fabris, S. Paganin, G. Leandro, P.J. Male, and E. Giostra Steatosis affects chronic hepatitis C progression in a genotype specific way Gut 53 3 2004 406 412
40. P.A. Gochee, J.R. Jonsson, A.D. Clouston, N. Pandeya, D.M. Purdie, and E.E. Powell Steatosis in chronic hepatitis C: association with increased messenger RNA expression of collagen I, tumor necrosis factor-alpha and cytochrome P450 2E1 J Gastroenterol Hepatol 18 4 2003 386 392
41. N. Zhu, A. Khoshnan, R. Schneider, M. Matsumoto, G. Dennert, and C. Ware Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis Virol J 72 5 1998 3691 3697
42. V. Paradis, G. Perlemuter, F. Bonvoust, D. Dargere, B. Parfait, and M. Vidaud High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis Hepatology 34 4 Pt 1 2001 738 744
43. Y. Kamada, S. Tamura, S. Kiso, H. Matsumoto, Y. Saji, and Y. Yoshida Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin Gastroenterology 125 6 2003 1796 1807
44. K. Moriya, K. Nakagawa, T. Santa, Y. Shintani, H. Fujie, and H. Miyoshi Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis Cancer Res 61 11 2001 4365 4370
45. M. Okuda, K. Li, M.R. Beard, L.A. Showalter, F. Scholle, and S.M. Lemon Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein Gastroenterology 122 2 2002 366 375
46. T. Tsutsumi, T. Suzuki, T. Shimoike, R. Suzuki, K. Moriya, and Y. Shintani Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity Hepatology 35 4 2002 937 946
47. L. Castera, C. Hezode, F. Roudot-Thoraval, I. Lonjon, E.S. Zafrani, and J.M. Pawlotsky Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis Gut 53 3 2004 420 424
48. P. Angulo Nonalcoholic fatty liver disease N Engl J Med 346 16 2002 1221 1231
49. S.A. Harrison, and A.M. Di Bisceglie Advances in the understanding and treatment of nonalcoholic fatty liver disease Drugs 63 22 2003 2379 2394
50. I.J. Hickman, A.D. Clouston, G.A. Macdonald, D.M. Purdie, J.B. Prins, and S. Ash Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C Gut 51 1 2002 89 94
51. B.A. Neuschwander-Tetri, E.M. Brunt, K.R. Wehmeier, D. Oliver, and B.R. Bacon Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone Hepatology 38 4 2003 1008 1017
52. K. Promrat, G. Lutchman, G.I. Uwaifo, R.J. Freedman, A. Soza, and T. Heller A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis Hepatology 39 1 2004 188 196